Sanofi Fights Bid To Combine EpiPen Suits Against Mylan

By Melissa Daniels (May 15, 2017, 7:09 PM EDT) -- Sanofi-Aventis U.S. LLC urged the Judicial Panel on Multidistrict Litigation on Friday to deny a request to join its suit against Mylan Inc. over an alleged monopoly of EpiPen sales with others, saying its Sherman Act suit brings up different legal issues than putative class actions from direct and indirect purchasers of the pens.

Plaintiffs in a New Jersey federal putative class action in April filed a motion asking the JPML to transfer several actions against Mylan over EpiPen's pricing and anti-competitive conduct into the district of New Jersey and consolidate or coordinate them for pretrial proceedings.

But Sanofi said Friday its...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!